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Abstract
Aims/hypothesis According to the consensus criteria devel-
oped for type 1 diabetes, an individual can be diagnosed with
insulitis when ≥ 15 CD45+ cells are found within the paren-
chyma or in the islet–exocrine interface in ≥ 3 islets. The aim
of this study was to determine the frequency of individuals
with type 2 diabetes fulfilling these criteria with reference to
non-diabetic and type 1 diabetic individuals.
Methods Insulitis was determined by examining CD45+ cells
in the pancreases of 50, 13 and 44 organ donors with type 2
diabetes, type 1 diabetes and no diabetes, respectively. CD3+
cells (T cells) infiltrating the islets were evaluated in insulitic
donors. In insulitic donors with type 2 diabetes, the pancreases
were characterised according to the presence of CD68 (mac-
rophages), myeloperoxidase (MPO; neutrophils), CD3, CD20
(B cells) and HLA class I hyperstained islets. In all type 2
diabetic donors, potential correlations of insulitis with dynam-
ic glucose-stimulated insulin secretion in vitro or age, BMI,
HbA1c or autoantibody positivity were examined.
Results Overall, 28% of the type 2 diabetic donors fulfilled
the consensus criteria for insulitis developed for type 1 diabe-
tes. Of the type 1 diabetic donors, 31% fulfilled the criteria.
None of the non-diabetic donors met the criteria. Only type 1
diabetic donors had ≥ 15 CD3+ cells in ≥ 3 islets. Type 2
diabetic donors with insulitis also had a substantial number
of CD45+ cells in the exocrine parenchyma. Macrophages
constituted the largest fraction of CD45+ cells, followed by
neutrophils and T cells. Of type 2 diabetic pancreases with
insulitis, 36% contained islets that hyperstained for HLA class
I. Isolated islets from type 2 diabetic donors secreted less
insulin than controls, although with preserved dynamics.
Insulitis in the type 2 diabetic donors did not correlate with
glucose-stimulated insulin secretion, the presence of autoanti-
bodies, BMI or HbA1c.
Conclusions/interpretation The current definition of insulitis
cannot be used to distinguish pancreases retrieved from indi-
viduals with type 1 diabetes from those with type 2 diabetes.
On the basis of our findings, we propose a revised definition
of insulitis, with a positive diagnosis when ≥ 15 CD3+ cells,
not CD45+ cells, are found in ≥ 3 islets.
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Abbreviations
DiViD Diabetes Virus Detection
ICA Islet cell autoantibodies
MPO Myeloperoxidase
nPOD Network for Pancreatic Organ Donors with Diabetes
Introduction
In type 1 diabetes, leucocyte infiltration of islets (insulitis) has
a presumed central role in beta cell destruction and has been
regarded evidence for an autoimmune aetiology of the disease
[1, 2]. Different criteria have been used to define insulitis [2],
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making it difficult to compare and analyse results from differ-
ent studies. A consensus opinion was recently reached on the
criteria for insulitis: a patient is diagnosed with insulitis when
a lesion is established in a minimum of three islets with a
threshold level of ≥ 15 CD45+ cells within the islet parenchy-
ma or in the islet–exocrine interface [1]. CD45, also known as
protein tyrosine phosphatase receptor type C, is an enzyme
speci f ica l ly expressed on haematopoie t ic ce l l s .
Macrophages, neutrophils, T cells and B cells have been re-
ported to be part of the insulitic infiltrate in type 1 diabetes
[2–5]. At the time when the consensus definition was
established, seven was the highest number of CD45+ cells
found in islets from 61 non-diabetic control pancreases exam-
ined in the Network for Pancreatic Organ Donors with
Diabetes (nPOD) [1, 6], and thus the consensus definition
adequately separated non-diabetic controls from individuals
with type 1 diabetes.
Inflammation of the pancreas has been suggested to be part
of the aetiopathology of type 2 diabetes [7]. Supporting this
theory, an elevated number of macrophages have been detect-
ed in islets of type 2 diabetes patients in conjunction with
increased levels of cytokines and chemokines [8]; CD8+ cells
and macrophages have also been found to be elevated in the
exocrine compartment in type 2 as well as type 1 diabetes [9,
10]. Furthermore, IL-1 receptor antagonist treatment of type 2
diabetes patients reduces HbA1c and enhances C-peptide
levels, but does not alter insulin resistance [11], suggesting a
direct role of inflammation in type 2 diabetes islet dysfunc-
tion. Collectively, these observations suggest that inflamma-
tion of the pancreas plays a prominent pathogenic role in type
2 diabetes.
In this study we determined the frequency of individuals
diagnosed with type 2 diabetes fulfilling the definition of
insulitis according to the consensus criteria developed for type
1 diabetes. Further, in pancreases with insulitic lesions, the
number of macrophages, neutrophils, T cells and B cells was
determined. In addition, other morphological hallmarks for
type 1 diabetes were evaluated in the type 2 diabetic
pancreases, such as islets without beta cells [2, 12, 13] or the
presence of HLA class I hyperstaining in the islets [14, 15].
Finally, potential correlations between the presence of insulitic
lesions and glucose-stimulated insulin secretion in vitro or
clinical characteristics such as age, BMI, HbA1c and autoan-
tibody positivity of the donor were examined.
Methods
Human pancreatic specimens Biopsies from the pancreases
of 50 donors with type 2 diabetes based on established clinical
diagnosis or on HbA1c > 6.5% (48 mmol/mol) [16], 13 donors
with type 1 diabetes and 44 previously healthy organ donors
with HbA1c < 6.0% (42 mmol/mol) were included in the
study. The medical records of the donors were not made avail-
able in order to protect the integrity of the deceased person,
but most donors with type 2 diabetes had been diagnosed for
several years. Of the type 1 diabetic donors, two died at onset
(described previously in Korsgren et al [5]) and 11 had been
diagnosed for > 1 year. Consent for organ donation (for clin-
ical transplantation and for use in research) was obtained ver-
bally from the deceased’s next of kin by the attending physi-
cian and was documented in the medical records of the
deceased in accordance with Swedish law and as approved
by the Regional Ethics Committee (Dnr 2015/444). The type
2 diabetes donors were, on average, aged 63 years (range 44–
85) with BMI 28 kg/m2 (range 20–42). The non-diabetic do-
nors were matched for age (59 years [42–72]), sex and BMI
(27 kg/m2 [21–46]) to the type 2 diabetes donors. The donors
with type 1 diabetes had a mean age of 39 years (16–68). The
pancreatic tails of the type 2 diabetes donors were used for
islet isolation, and tissue samples were taken from the pancre-
as, fixed in paraformaldehyde and embedded in paraffin. One
to two tissue samples from different parts of the type 2 diabe-
tes pancreases, one tissue sample from the head of the non-
diabetic pancreas collected during the process of clinical islet
isolation, and a minimum of two samples from different parts
of the type 1 diabetes pancreases were included in the study.
Immunohistochemical stainingConsecutive sections (6μm)
from each tissue sample block were processed and labelled
using a standard technique. All antigens were unmasked by
heat-induced antigen retrieval using buffered sodium citrate or
EDTA according to the manufacturer’s instructions (Dako,
Glostrup, Denmark). Antibodies against synaptophysin and
CD45 (electronic supplementary material [ESM] Table 1)
were applied. In donors with insulitis (≥15 CD45+ cells in ≥
3 islets), sections consecutive to the section stained for
synaptophysin/CD45 were stained for CD68 (macrophages),
myeloperoxidase (MPO; granulocytes), CD3 (T cells), CD20
(B cells), insulin and glucagon, HLA class I ABC and active
caspase 3. Human spleen sections were used as a positive
control for all antibodies except caspase 3 and HLA, for which
human tonsil sections were used. Negative controls had the
primary antibody replaced by buffer. Immunohistochemical
reactions were performed on paraffin tissue sections using a
manual method or an automated immunohistochemical stainer
(Autostainer Link 48, Dako, Glostrup, Denmark). All bound
primary antibodies except caspase-3 were visualised using
Dako EnVision and diaminobenzidine (DAB)-based substrate
or double stained using EnVision G/2 Doublestain System,
Rabbit/Mouse (DAB+/Permanent Red). Caspase-3 antibodies
were visualised using MACH1 Universal HRP-Polymer
Detection kit (Biocare Medical, Concord, CA, USA).
Sections were counterstained with haematoxylin and
analysed using a light microscope (Leica DM 2000
LED, Wetzlar, Germany).
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Analysis Donors were diagnosed with insulitis when ≥ 15
CD45+ cells within the islet parenchyma and/or in the islet–
exocrine interface were found in ≥ 3 islets. CD45+ cells adjacent
to an islet or in direct contact with other CD45+ cells within the
peri-insulitic cap were counted as being part of the insulitic
lesion. A total of 250 (SD= 189), 118 (SD= 54) and 48
(SD=36) islets per donor were analysed for insulitis in type 2
diabetic, type 1 diabetic and non-diabetic donors, respectively.
At the time of analysis, the examiner knew only the disease
status of the donor. In donors diagnosed with insulitis, the num-
ber of CD3+ cells associatedwith islets were counted in the same
manner as CD45+ cells and the number of cells stained for active
caspase-3were counted in islets. Insulin and glucagon content in
islets was estimated and insulin-deficient islets were noted.
In type 2 diabetic donors, the disposition and amount of con-
nective tissue, acinar tissue, endocrine tissue and CD45+ immune
cells were evaluated in all sections stained for CD45 and
synaptophysin. The pancreatic tissue was graded according to
the presence of CD45+ cells: (1) only a fewCD45+ cells, scattered
in the pancreatic tissue (example in Fig. 1e); (2) an intermediate
number of CD45+ cells; and (3) intense CD45+ inflammation,
with immune cells infiltrating the tissue in large numbers (exam-
ples in Fig. 1a–d). In insulitic type 2 diabetic donor sections,
CD45+ cells were quantified by counting in a randomly selected
area of approximately 1 mm2, and CD68+, MPO+, CD3+ and
CD20+ cells were counted in the corresponding area in consecu-
tive sections. A donor was diagnosed with HLA class I
hyperstaining when one or more islets within a pancreas
displayed intense staining for HLA class I ABC. Clinical data
regarding age, BMI, HbA1c and autoantibody positivity, collected
by the Nordic Network for Islet Transplantation, were compared
between non-insulitic and insulitic type 2 diabetes donors.
Insulin secretion Islets were isolated using a standard proto-
col [17]. One day after isolation, glucose-stimulated insulin
secretion was assessed in a dynamic perifusion system,
Suprafusion 1000 (BRANDEL, Gaithersburg, MD, USA).
Twenty handpicked islets were perifused with low glucose
(1.67 mmol/l) for 42 min, high glucose (20 mmol/l) for
48 min, and then low glucose again. Fractions were collected
at different time points and secreted insulin was measured
using insulin ELISA (Mercodia, Uppsala, Sweden).
Statistical analysis GraphPad Prism software (version 6.0 h)
was used for statistical analysis. The Mann–Whitney U test
was used to compare age, BMI and HbA1c between non-
insulitic and insulitic type 2 diabetic donors. A p value <
0.05 was considered statistically significant.
Results
Type 2 diabetic donors fulfilled the consensus criteria for
insulitisUsing the consensus definition of insulitis from 2013
(≥3 islets with ≥ 15 CD45+ cells), 14 out of 50 (28%) type 2
diabetic donors fulfilled the criteria for insulitis. In these
donors, the mean frequency of insulitic islets was 2.8%
(SD=2.3). CD45+ cells were also found scattered in the exo-
crine tissue (Fig. 1a, b), with no obvious association with
islets. Insulitic islets occurred in seven of 36 pancreases con-
taining a low density of CD45+ cells in the exocrine pancreas,
six of 13 pancreases containing an intermediate density of
CD45+ cells and one of one pancreas containing an intense
density of CD45+ cells (Fig. 1a, b). Of 50 type 2 diabetic
donors, 41 (82%) were diagnosed with insulitis using the old
definition of insulitis (≥3 islets with ≥ 5 CD45+ cells) [2].
Of 50 donors with type 2 diabetes, 17 had fibrotic areas
with islets (Fig. 1c, d). In 15 of these 17 cases, the fibrotic area
was also rich in CD45+ cells, and consequently, some of the
islets fulfilled the criteria for insulitis, i.e. six of these donors
were diagnosed with insulitis. The intensity of inflammation
appeared heterogeneous between different lobes within a type
2 diabetic pancreas, as well as between individuals (Fig. 1e).
In the type 1 diabetic group, four of 13 donors (31%)—includ-
ing both of those with acute-onset disease—were diagnosed
with insulitis. The mean frequency of insulitic islets in these
donors was 4.2% (SD=1.8). None of the non-diabetic donors
fulfilled the consensus definition criteria. Indeed, only one
Fig. 1 Insulitis in type 2 diabetes. Pancreatic sections were stained for
CD45 (brown) and synaptophysin (red). Representative pictures are
shown of areas in the pancreas with insulitic islets and a high density of
CD45+ cells (a, b) and of fibrotic areas with islets and a rich amount of
CD45+ cells (c, d). Some type 2 diabetic pancreases contained few
CD45+ cells, as illustrated in (e). Parts (a, b), (c, d), and (e) are from three
different donors with type 2 diabetes. Scale bars, 100 μm
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islet of a total of 2130 islets in non-diabetic donors had ≥ 15
CD45+ cells. Ten of 13 type 1 diabetic donors and ten of 44
non-diabetic donors fulfilled the old criteria for insulitis (≥3
islets with ≥ 5 CD45+ cells).
Macrophages were the most frequent immune cell in the
insulitic type 2 diabetic pancreases In the 14 insulitic type 2
diabetic pancreases, on average 102 CD68+ cells were found
per mm2. In addition, MPO and CD3+ cells were regularly
found (49 and 20 cells/mm2, respectively) (Fig. 2a–f).
CD20+ cells were found only occasionally. The highest num-
ber of CD3+ cells found within and/or at the periphery of an
islet was 18; multiple islets were also found with 6–10 CD3+
cells (Fig. 2g), but there were no findings of ≥ 15 CD3+ cells
in ≥ 3 islets. In comparison, both donors with acute-onset type
1 diabetes had ≥ 3 islets with ≥ 15 CD3+ cells (6/51 and 3/38
islets, respectively), whereas none of the two insulitic donors
with long-standing type 1 diabetes fulfilled this criterion
(0/128 and 2/54 islets with ≥ 15 CD3+ cells, respectively).
Activated caspase-3 was rarely found in insulitic donors,
with a frequency of 1–2 positive cells per 100 islets and with
no apparent difference between individuals with type 2 diabe-
tes and long-standing type 1 diabetes. However, positive cells
were found at about ten times higher frequency in the donors
with acute-onset type 1 diabetes.
Insulin-deficient islets were rare in insulitic type 2 diabetic
pancreases Most islets in the type 2 diabetic individuals
contained both insulin- and glucagon-positive cells
(Fig. 3a, b). In total, fewer than five islets devoid of beta cells
were found from all of the 2831 islets examined in insulitic
type 2 diabetic pancreases. Insulitis was most commonly
found in islets containing both insulin- and glucagon-
positive cells, but could also be found in the rare islets
consisting of only a few insulin-positive cells (Fig. 3c, d). In
contrast, all the pancreases of type 1 diabetic donors contained
insulin-deficient islets. Both donors with acute-onset type 1
diabetes and one donor with long-standing type 1 diabetes had
numerous insulin-containing islets. These donors also fulfilled
the criteria for insulitis according to the consensus definition.
The remaining ten donors with long-standing type 1 diabetes
had almost solely insulin-deficient islets, but a few scattered
























Fig. 2 CD68+ cells were the most prominent immune cell type in
insulitic type 2 diabetic pancreases. The densities of CD45+ (a), CD68+
(b), MPO+ (c), CD3+ (d) and CD20+ (e) cells were determined in con-
secutive sections in each type 2 diabetic donor diagnosed with insulitis.
All images (a–e) are from one donor. Synaptophysin was stained red in
(a) and immune cells were stained brown. The densities of immune cells
were compared in 14 donors with type 2 diabetes (g). The red dots in (g)
represent the donor from whom the samples used in (a–e) were taken,
with relatively high numbers but typical distribution of immune cells. The
blue dots represent a donor who had several islets with relatively many
islet-associated CD3+ cells (7, 9 and 10 CD3+ cells in three different
islets). One such islet is depicted in (f). Scale bars, 100 μm
Fig. 3 Insulitis affected islets regardless of insulin content. (a, c) Islets
stained for insulin (brown) and glucagon (red). A representative islet with
‘normal’ distribution of insulin and glucagon (a) and an islet with few
insulin-positive cells (c) are shown. (b, d) The same islets in consecutive
sections stained for CD45 (brown) and synaptophysin (red). Parts (a, b)
and (c, d) are from two different donors. Scale bars, 100 μm
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HLA class I hyperstained islets occurred in insulitic type 2
diabetic donors Five of 14 (36%) of the insulitic type 2 dia-
betic pancreases contained at least one islet with intense stain-
ing for HLA class I (see Fig. 4 for representative pictures).
This hyperstaining affected islets both with and without
insulitis.
Glucose-stimulated insulin secretion was similar in type 2
diabetic donors with and without insulitisWhen stimulated
with high glucose in a dynamic perifusion assay, isolated islets
from type 2 diabetic donors secreted less insulin, although
with preserved dynamics, compared with age-, BMI- and
sex-matched non-diabetic controls (n=38). No differences
regarding the dynamics and amounts of insulin release were
found between insulitic (n= 9) and non-insulitic (n= 27)
donors (Fig. 5).
Type 2 diabetic donors with and without insulitis did not
have different clinical characteristics There were no sig-
nificant differences regarding BMI or HbA1c between
the non-insulitic and insulitic type 2 diabetic donors
(Fig. 6a, b). Age was higher in the group of insulitic
type 2 diabetic donors compared with non-insulitic do-
nors (Fig. 6c). One type 2 diabetic donor had autoanti-
bodies against GAD65, two donors had islet cell anti-
bodies (ICA) and antibodies against GAD65 and one
donor had ICA and antibodies against GAD65 and zinc
transporter 8 (ZNT8). None of these autoantibody-
positive donors fulfilled the criteria for insulitis.
Discussion
The current definition of insulitis cannot be used to distinguish
pancreases retrieved from individuals with type 1 diabetes
from those with type 2 diabetes, as in this study insulitis was
found in 31% and 28% of individuals, respectively. The biop-
sies analysed in this study were of high quality as the
pancreases were procured from heart-beating organ donors.
A limitation of our study is that the medical records of the
donors were not made available in order to protect the integ-
rity of the deceased person. However, most individuals had
been diagnosed with type 2 diabetes for several years. In a
meta-analysis, insulitis defined by the less stringent criteria of
≥ 5 CD45+ cells in ≥ 3 islets was present in 56% of individuals
with type 1 diabetes examined within the first month of diag-
nosis and in only four of 132 individuals (3%) examined
> 1 year after diagnosis [2].
The consensus definition of insulitis was adopted at the
nPOD meeting in February 2013 and published in
November 2013 in an effort to enhance understanding of the
pathogenesis of type 1 diabetes and to allow comparisons
between histopathological studies [1]. CD45 was chosen as
a marker for immune cells because the insulitic infiltrates in
type 1 diabetes include T cells (predominantly CD8+ but also
CD4+ cells), B cells, macrophages and granulocytes [1, 3, 5].
This definition was designed to distinguish pancreases from
individuals with type 1 diabetes from pancreases with back-
ground inflammatory infiltrates, as observed in non-diabetic
individuals [1]. Since then, few publications have adopted this
more stringent definition of insulitis. The findings presented in
this study call for a revision of the definition in order to allow
pancreases from individuals with type 1 diabetes to be distin-
guished from those with type 2 diabetes. Furthermore, in a
recent study of non-diabetic autoantibody-negative donors,
four of eight individuals fulfilled the criteria for insulitis
[12], further reinforcing the need to revise the current defini-
tion of insulitis.
The highest number of CD3+ cells within or adjacent to an
islet from an individual with type 2 diabetes in the present study
was 18 and we found multiple islets containing 6–10 CD3+
cells. We therefore suggest that an insulitic islet should be
redefined so that a lesion can be established when ≥ 15 CD3+
cells are present in one section, within the islet parenchyma or















Fig. 5 Glucose-stimulated insulin secretion in islets isolated from type 2
diabetic donors. Isolated islets were stimulated in a dynamic perifusion
assay. Insulin secretion was compared between age-, BMI- and sex-
matched non-diabetic controls (n = 38, triangles), and non-insulitic
(n = 27, circles) and insulitic type 2 diabetic donors (n = 9, squares).
Error bars show SEMs
Fig. 4 HLA class I hyperstained islets were found in type 2 diabetic
pancreases. HLA class I (brown) in insulitic type 2 diabetic donors.
Representative islets graded as non-hyperstained (a) and hyperstained
(b) are shown. Parts (a) and (b) are from two different donors. Scale bars,
100 μm
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in the islet–exocrine interface. The disease process in type 1
diabetes is heterogeneously distributed within the pancreas
[13]. Therefore, the presence of insulitis should preferentially
be examined in multiple lobes of the pancreas. However, the
limited availability of well-preserved human pancreases means
this may not always be possible. The human pancreas contains
several millions of islets of hugely varying size; small islets
composed of only a few endocrine cells dominate and islets
with a diameter of more than 250 μm are only rarely found
[18–20]. Obviously, the size of an islet will influence the
number of immune cells present per islet. Based on these con-
siderations, specifying the number of islets in the definition of
insulitis (i.e. ≥ 3 islets) should, if possible, be avoided. Instead,
the proportion of islets with infiltrating CD3+ cells provides a
better diagnostic criterion. In addition, the variation in islet size
suggests that at least 50, but preferably 100, islets should be
examined. In an effort to adhere to the consensus definition, it is
proposed that if < 100 islets are available for evaluation, ≥ 3
islets should contain ≥ 15 CD3+ cells. However, if ≥100 islets
are available for evaluation, ≥ 3% should contain ≥ 15 CD3+
cells (see text box: proposed definitions of insulitis). Using this
definition for type 1 diabetes, both of the acute-onset type 1
diabetic donors included in this study and six out of six
individuals with recent-onset type 1 diabetes examined within
the Diabetes Virus Detection (DiViD) study fulfil the criteria
[13], i.e. 11% of all examined islets in theDiViD study had ≥ 15
CD3+ cells. Furthermore, the proposed definition would
adequately distinguish between individuals with type 1 diabetes
and type 2 diabetes, as none of the 50 type 2 diabetic donors
included in this study fulfilled these criteria. An adjusted
definition of insulitis may also be applied to type 2 diabetes
(see text box). The proposed definition for insulitis in type 2
diabetes was fulfilled by 28% of individuals with type 2 diabe-
tes. This definition is, however, unable to discriminate between
type 2 diabetes and type 1 diabetes. Therefore, based on the
findings presented here, it is proposed that the discrimination of
type 1 diabetes and type 2 diabetes should be based on the
presence of insulin-deficient islets.
The recruitment of immune cells in type 2 diabetic
pancreases has been proposed to be caused by beta cell stress
[8]. However, the CD45+ cells found within the pancreases in
this study were not preferentially located to the islets, but were
seemingly randomly distributed throughout the entire gland.
An increased presence of immune cells in the exocrine pan-
creas has been reported previously in both type 2 and type 1
diabetes [9, 10]. Accumulations of CD45+ cells were frequent-
ly found in areas of fibrosis, in which islets were densely
surrounded by clusters of immune cells. Fibrosis constitutes
the end stage of inflammation and it is likely that cellular
inflammationmaintained several years after diagnosis contrib-
utes to the loss of exocrine as well as endocrine parenchyma in










































































a b cFig. 6 Clinical characteristics of
non-insulitic and insulitic type 2
diabetic donors. Non-insulitic and
insulitic type 2 diabetic donors
were compared for HbA1c, BMI
and age. Each black dot
represents the value from one
donor. The horizontal bar shows
the mean value; p < 0.05 was
considered statistically
significant. To convert values for
HbA1c in DCCT % into
mmol/mol, subtract 2.15 and
multiply by 10.929. T2D, type 2
diabetes





 cells present in one section within 
the islet parenchyma or in the islet exocrine 
interface
≥3 insulitic islets if <100 islets are available for 
evaluation, or





 cells present in one section within 
the islet parenchyma or in the islet exocrine 
interface
Individual with insulitis
≥3 insulitic islets if <100 islets are available for 
evaluation, or
≥3% insulitic islets if ≥100 islets are available 
for evaluation
 Proposed new definition of insulitis in T2D
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by CD45+ cells, mainly CD68+ macrophages, may also direct-
ly affect islet function and survival, arguing for a direct role of
these cells in the pathogenesis of type 2 diabetes. Supporting
this notion, laser capture-microdissected islets from type 2
diabetic pancreases show cytokine and chemokine patterns
that suggest a sustained mild inflammation affecting the islets
[22, 23] and possibly contributing to islet dysfunction. This
notion was not, however, supported by the functional charac-
terisation of isolated islets in the present study. Even though
we found a pronounced decrease in glucose-stimulated insulin
release in islets isolated from pancreases obtained from indi-
viduals with type 2 diabetes when compared with islets from
non-diabetic individuals, no difference in function could be
observed between islets from type 2 diabetes donors with and
without insulitis. Similarly, insulitis did not correlate with the
level of HbA1c. These functional observations should, how-
ever, be interpreted with caution—technical limitations mean
we do not have information on insulitis in the actual islets
examined in vitro, and HbA1c critically depends on the inten-
sity of diabetes treatment.
No correlation could be found between insulitis and the
presence of islet autoantibodies in the type 2 diabetic donors.
This should, however, be interpreted with caution as only 8%
of the individuals with type 2 diabetes in our study had one or
more autoantibodies. Although markedly higher than in non-
diabetic individuals, the frequency of autoantibodies in chil-
dren or adolescents diagnosed with type 2 diabetes has in
larger studies been reported to be as high as 30% [24]. Lack
of insulitis in individuals with autoantibodies has been report-
ed previously [25], and suggests that autoantibodies may ap-
pear in response to beta cell damage without being accompa-
nied by a cellular immune response infiltrating the islets.
In addition to insulitis, other morphological characteristics of
type 1 diabetes are also present in the pancreases of individuals
with type 2 diabetes, for example HLA class I hyperstaining.
However, the frequent finding of islets devoid of beta cells in
pancreases obtained from individuals with recent-onset as well
as long-standing type 1 diabetes is not found in individuals with
type 2 diabetes. Thus, the appearance of insulin-deficient islets
constitutes the main morphological criterion able to distinguish
type 1 diabetic pancreases from type 2 diabetic pancreases,
even though the loss of beta cells in type 1 diabetes varies
greatly, especially at the onset of disease [13]. These observa-
tions indicate that leucocyte infiltration of islets has different
immunopathological roles in type 1 diabetes and type 2 diabe-
tes, a notion also supported by the higher proportion of T cells
in the insulitic lesions in type 1 diabetes [2].
Insulitis is considered one of the major morphological hall-
marks of type 1 diabetes. The findings presented show that the
current consensus definition of insulitis [1] is not sufficient to
separate the ongoing inflammation in the pancreas in individ-
uals with type 1 diabetes from that occurring in those with type
2 diabetes. A modification of the definition of insulitis is
therefore warranted. Based on our findings in a large cohort
of type 2 diabetic donors, we propose that the diagnosis should
bemade when ≥ 15 CD3+ cells, not CD45+ cells, are found in ≥
3 islets.
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